Key facts
- Notable investors include Innovationsstarter, IFB Bank Hamburg.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for iduneo
- ·The full record, as it builds
Funding rounds
No funding rounds for iduneo are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About iduneo
Developer of an oncology clinical trial recruitment platform designed to improve patient access to cancer therapies. The company transforms clinical trial recruitment through direct patient engagement and seamless hospital network integration and offers services such as patient identification, pre-screening, and referral to research sites, leveraging digital platforms and data analytics to target and engage potential participants, as well as custom prescreened, enabling patients with access to advanced therapies and accelerating clinical research.
- Sector
- Healthcare
- HQ
- Hamburg, Germany
- Founded
- 2024
- Employees
- 3
- Website
- iduneo.com/
- Ownership
- Privately Held (backing)
iduneo doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in iduneo shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on iduneo in its N-PORT filings yet. We sweep new filings monthly.